<DOC>
	<DOC>NCT01108978</DOC>
	<brief_summary>The purpose of this study is to evaluate the Efficacy and Safety of Dehypotin® in the Patients with Type 2 Diabetes Mellitus or Cardiovascular Disease. Eligible patients will be randomly assigned to 1 of 2 arms, either Dehypotin® or placebo, and will receive the diet advisement throughout the study.</brief_summary>
	<brief_title>Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Male or female Age 2075 years Diagnosis of type II Diabetes Mellitus for at least 3 months and/or clinical evident cardiovascular disease (CVD) A hemoglobin A1c concentration has to be &lt; 8% before screening Women of child bearing potential who are pregnant, breastfeeding or not using effective contraceptives Known hypersensitivity to Pravastatin or any of its components Have a history of homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia Significant medical illness Known serious conditions, e.g. serum creatine kinase(CK)levels 2.5 times upper limit of normal Subjects being treated with drugs influence serum lipid concentrations Subjects who have cancer or been receiving the cancer chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>hypercholesterolemia</keyword>
</DOC>